EDIT Editas Medicine
- 3.925
- +0.175+4.67%
Editas Medicine News
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough
We're Keeping An Eye On Editas Medicine's (NASDAQ:EDIT) Cash Burn Rate
Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Express News | Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7
BofA Upgrades Editas to Buy, Cites Reni-cel Progress
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
Express News | Editas Medicine Shares Are Trading Higher After B of A Securities Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $13 to $15
Earnings Call: Editas Medicine Optimistic Despite HHS Decision
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Barclays Remains a Hold on Editas Medicine (EDIT)
Buy Rating on Editas Medicine as R&D Progress Signals Market Potential for Sickle Cell and Thalassemia Treatments
Editas Medicine Price Target Raised to $15.00/Share From $13.00 by B of A Securities
Editas Medicine Raised to Buy From Neutral by B of A Securities
Editas Medicine Analyst Ratings
Truist Securities Adjusts Price Target on Editas Medicine to $12 From $20, Maintains Buy Rating
Express News | Editas Medicine, Inc : Barclays Cuts Target Price to $7 From $9
Analysis
Price Target
No Data
No Data
